Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed Device Submissions Workshop In Brief

This article was originally published in The Gray Sheet

Executive Summary

New 510(k) paradigm: Level 2 guidance document on 510(k)s is expected to be released by the end of the summer, Office of Device Evaluation Premarket Notification Staff Director Heather Rosecrans tells attendees at AdvaMed's device submissions workshop held June 6-7 in Rockville, Maryland. "We're right at the process of updating the new paradigm, and that's going to go through the GGP [good guidance practices] process. We're going to consider the truthful and accurate...statement in place of the declaration of conformity...with design controls, because there's no end and no beginning and there has been some confusion." Rosecrans highlighted one change for manufacturers submitting 510(k)s: "validation will have to be completed prior to going to market with your device"...

You may also be interested in...



Regulatory News In Brief

Hako-Med petition: Honolulu firm's April 23 petition requesting that low-voltage electrode lead wires in the vacuum hose of the VacuPulls/VasoPulse be exempted from the performance standard for electrode lead wires and patient cables (21 CFR 898) is denied by FDA. "In this instance, the public health derives no benefit from the continued use of non-compliant electrode lead wires that is not already provided by equivalent powered muscle stimulator and powered peripheral nerve stimulator devices that use compliant electrode wires," the agency writes in the Aug. 30 denial letter. "The continued marketing of unprotected electrode leads and patient cables, no matter how they are labeled, presents an unreasonable and substantial risk of illness or injury to individuals"...

Regulatory News In Brief

Hako-Med petition: Honolulu firm's April 23 petition requesting that low-voltage electrode lead wires in the vacuum hose of the VacuPulls/VasoPulse be exempted from the performance standard for electrode lead wires and patient cables (21 CFR 898) is denied by FDA. "In this instance, the public health derives no benefit from the continued use of non-compliant electrode lead wires that is not already provided by equivalent powered muscle stimulator and powered peripheral nerve stimulator devices that use compliant electrode wires," the agency writes in the Aug. 30 denial letter. "The continued marketing of unprotected electrode leads and patient cables, no matter how they are labeled, presents an unreasonable and substantial risk of illness or injury to individuals"...

RAPS In Brief

FDA's James Dillard: Deputy Director Bram Zuckerman will become acting director of FDA's Division of Cardiovascular and Respiratory Devices Dec. 3. Current DCRD Director James Dillard departs Nov. 30 for the private sector, where he has accepted the position of VP-science and technology at U.S. Tobacco. Dillard, a fourteen-year FDA veteran, has held the DCRD position for the last 18 months and overseen the reorganization of the division (1"The Gray Sheet" July 24, 2000, p. 10)...

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel